Ziprasidone
| Price | $1 |
| Package | 1KG |
| Min. Order: | 1G |
| Supply Ability: | 100KG |
| Update Time: | 2019-07-06 |
Product Details
| Product Name: Ziprasidone | CAS No.: 146939-27-7 |
| Min. Order: 1G | Purity: 98% |
| Supply Ability: 100KG | Release date: 2019/07/06 |
AD68
| Ziprasidone Basic information |
| Atypical antipsychotic Dosage and usage Uses Production method |
| Product Name: | Ziprasidone |
| Synonyms: | Ziprasidone HBr;5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one;Geodon;Ziprasidone solution;5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one;ZIPRASIDONE-D8;5-[2-[4-(1,2-Benzisothiazol-3yl)-1-piperazinyl-d8]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one;2H-Indol-2-one, 5-2-4-(1,2-benzisothiazol-3-yl)-1-piperazinylethyl-6-chloro-1,3-dihydro- |
| CAS: | 146939-27-7 |
| MF: | C21H21ClN4OS |
| MW: | 412.94 |
| EINECS: | 203-794-9 |
| Product Categories: | Isotope Labelled Compounds;Sulfur & Selenium Compounds;API;Geodon, Zeldox;Other APIs;Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals;Heterocycles |
| Mol File: | 146939-27-7.mol |
 |
|
| Ziprasidone Chemical Properties |
| Melting point | 213-215°C |
| storage temp. | Refrigerator |
| Merck | 14,10171 |
| CAS DataBase Reference | 146939-27-7(CAS DataBase Reference) |
| Safety Information |
| Hazard Codes | F,T |
| Risk Statements | 60-61-11-19-38 |
| Safety Statements | 53-45 |
| RTECS | NM3241000 |
| MSDS Information |
| Ziprasidone Usage And Synthesis |
| Atypical antipsychotic | Ziprasidone is an atypical antipsychotic and belongs to piperazine benzothiazole compound. For in vitro condition, the product has a very high affinity to the dopamine D2, D3, 5-HT2A, 5-HT2C, 5-HT1A, 5-HT1D and α1 adrenergic receptor while having a moderate affinity to the histamine H1 receptor. However, it has antagonistic effect on dopamine D1, D2, 5-HT2A, 5-HT1D receptor while having agonistic effect on the 5-HT1A receptor. The product is capable of inhibiting the reuptake of 5-HT and norepinephrine via presynaptic membrane with the underlying mechanism of action remaining unclear. It may exert its anti-schizophrenia efficacy through the combined antagonist effect on dopamine D2 and 5-HT2 with the blocking strength being comparable to risperidone and haloperidol but stronger than olanzapine, quetiapine and clozapine. It is mainly used for the treatment of acute or chronic, onset or recurrent schizophrenia and is effective in treating both the negative as well as the positive symptoms of schizophrenia with especially a better efficacy in treating negative symptoms. It can reduce hallucinations, delusions, thought and action abnormal positive symptoms as well as alleviate the symptoms of mood monotonous and reduced volition activity and other negative symptoms. Atypical antipsychotics, also known as the new generation of antipsychotics, refers to a class of antipsychotics drug with its blockage effect on dopamine D2 receptor be weaker than its blockage effect on the 5-HT2A receptor. Clinical drugs at present such as clozapine, risperidone, olanzapine, quetiapine and ziprasidone all belongs to this category. For atypical antipsychotics, except clozapine which has a relative long history of clinical application (1970s), all these other drugs are new antipsychotics which did not emerge until the late 1990s. Atypical antipsychotics can not only block dopamine D2 receptors, but also more strongly block the effect of 5-HT2A receptor. When blocking the dopamine D2 receptor of midbrain-margin, it can also alleviate the positive symptoms; when blocking the 5-HT2A receptor on the presynaptic membrane of brain-cortical pathway, it can cause de-repressive release of dopamine and stimulate the dorsolateral dopamine D1 receptor of prefrontal cortex, alleviating the negative and cognitive symptoms, leading to excitement of the AVDM dopamine D1 receptors in the prefrontal cortex and the orbital part, further improving the symptoms of depression; when blocking the 5-HT2A receptor of the presynaptic membrane of the nigra-striatum pathway, it can cause the 5-HT2A receptor membranes, causing the de-repressive release of dopamine and can partially neutralizing the blocking effect of the drugs on the dopamine D2 receptor, therefore the extrapyramidal reactions are mild (long-term administration are also not easy to cause tardive dyskinesia); when causing blockage of the 5-HT2A receptor in the presynaptic membrane of the hypothalamic-funnel portion, it can cause de-repressive release of the dopamine, partially neutralizing the blocking effect of the drugs on the dopamine D2 receptor, therefore there is no obvious symptoms of hyperprolactinemia. It includes clozapine, olanzapine, quetiapine and ziprasidone. |
| Dosage and usage | The initial dose is 2 times per day with 20mg each time through oral administration. The bioavailability is usually bioavailability 30% with administration together with food being able to double the absorption of this product, reaching the bioavailability of 60%; administration with high-fat meal together can make the bioavailability be up to 97%. Adjustment of the dose can start at two days later, usually twice daily with the dose range being within 20~80mg and the maximum dose being 100mg. Patients of mild to moderate liver and kidney damage don’t need to adjust the dose. Ziprasidone is mainly metabolized in the liver with the metabolites being mainly excreted from the urine and partially discharged through fecal. The terminal T1/2 is about 7h. The above information is edited by the chemicalbook of Dai Xiongfeng. |
| Uses | It is a kind of antipsychotic and can be used as the antagonist of the dopamine D2-serotonin 5-HT2. |
| Production method | 6-Chloro-1,3-dihydro-2H-indol-2-ketone (I) and bromoacetic acid can have acylation reaction under the action of polyphosphoric acid to give the compound (II). And then be stirred together with silicon hydride and triethyl trifluoroacetic acid at room temperature to give the compound (III). Finally, it can have reaction with N-(3-benzisothiazole-yl) piperazine in MIBK containing sodium carbonate to give the product. |
| Chemical Properties | Tan Solid |
| Uses | Labelled Ziprasidone, which is used as an antipsychotic. Combined serotonin (5HT2) and dopamine (D2) receptor antagonist. |
| Uses | Ziprasidone (Geodon, Zeldox) was the fifth atypical antipsychotic to gain FDA approval. In the United States, Ziprasidone is approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation i |
| Uses | Labeled Ziprasidone, intended for use as an internal standard for the quantification of Ziprasidone by GC- or LC-mass spectrometry. |
| Definition | ChEBI: A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. |
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
![IMIDAZO[1,2-A]PYRIDIN-3-YL-ACETIC ACID](https://img.chemicalbook.com/ProductImageEN/2018-8/Large/fee842f2-9de6-4d7b-8cdc-353365461345.jpg)
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $65.00/10mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-10-31 | |
| $65.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-31 | |
| $1.00/1kg |
VIP2Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2024-01-24 | |
| $16.00/1KG |
Xiamen Wonderful Bio Technology Co., Ltd.
|
2023-06-06 | ||
| $150.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-05-29 | ||
| $100.00/1mg |
Shijiazhuang Gantuo Biotechnology Co., Ltd
|
2023-03-10 | ||
| $200.00/1kg |
Hebei Mingeng Biotechnology Co., Ltd
|
2022-11-27 | ||
| $0.00/1KG |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-09-07 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-23 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 |
China- Since: 2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com